Detalhe da pesquisa
1.
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Support Care Cancer
; 26(4): 1273-1279, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29090385